
    
      Study the effectiveness of the association of a short duration hormonal therapy by degarelix
      (Firmagon Â®) and radiotherapy, with radiotherapy alone on survival without events in the
      treatment of detectable PSA after radical prostatectomy.

      122 patients should be included over a period of 2 years. Patients will be treated according
      to the following scheme:

        -  Arm A (61 patients) : Pelvic Radiotherapy: 46 Gy and prostate only boost up to 66 Gy

        -  Arm B (61 patients) : Arm A + hormonal therapy by degarelix during 6 months
    
  